Vaxiion Therapeutics

Vaxiion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. Its lead product, VAX014, is a new alternative in oncolytic virus therapy and is currently in clinical trials for localized treatment of bladder cancer. Based on the clinical activity observed in bladder cancer patients and strong additional preclinical data, the company will soon initiate a clinical trial to locally deliver VAX014 to other solid tumor types.